<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-1 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-1</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-1</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of studies comparing neoadjuvant-adjuvant immunotherapy versus adjuvant-only immunotherapy in melanoma, including clinical outcomes, immunological mechanisms, and treatment protocols.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_name</strong></td>
                        <td>str</td>
                        <td>The name or identifier of the study or clinical trial (e.g. 'OpACIN-neo', 'SWOG S1801', etc.). Null if not specified.</td>
                    </tr>
                    <tr>
                        <td><strong>study_design</strong></td>
                        <td>str</td>
                        <td>Description of the study design (e.g. 'randomized phase II trial', 'phase III trial', 'retrospective analysis', 'mechanistic study', etc.)</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_regimen</strong></td>
                        <td>str</td>
                        <td>Detailed description of the immunotherapy treatment regimen, including specific drugs (e.g. 'pembrolizumab', 'nivolumab + ipilimumab'), dosing, and timing (neoadjuvant, adjuvant, or both).</td>
                    </tr>
                    <tr>
                        <td><strong>is_neoadjuvant_adjuvant</strong></td>
                        <td>bool</td>
                        <td>Does this treatment arm include neoadjuvant (pre-surgery) immunotherapy? True if yes, false if adjuvant only, null if unclear.</td>
                    </tr>
                    <tr>
                        <td><strong>is_adjuvant_only</strong></td>
                        <td>bool</td>
                        <td>Is this treatment arm adjuvant-only (post-surgery only)? True if yes, false if includes neoadjuvant, null if unclear.</td>
                    </tr>
                    <tr>
                        <td><strong>patient_population</strong></td>
                        <td>str</td>
                        <td>Description of the patient population, including melanoma stage, resectability status, and sample size (e.g. 'Stage III resectable melanoma, n=30').</td>
                    </tr>
                    <tr>
                        <td><strong>pathological_response</strong></td>
                        <td>str</td>
                        <td>Pathological response rates in neoadjuvant arm if reported (e.g. 'pCR 45%', 'major pathological response 60%'). Include percentages and definitions. Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>recurrence_free_survival</strong></td>
                        <td>str</td>
                        <td>Recurrence-free survival or event-free survival data, with timing and comparison between arms if available (e.g. '2-year RFS: 72% neoadjuvant vs 49% adjuvant, HR=0.58'). Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>overall_survival</strong></td>
                        <td>str</td>
                        <td>Overall survival data with timing and comparison between arms if available (e.g. '3-year OS: 88% vs 77%'). Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>immune_mechanisms_identified</strong></td>
                        <td>str</td>
                        <td>Detailed description of any immunological or biological mechanisms identified that explain why neoadjuvant treatment may be superior (e.g. 'increased CD8+ T cell infiltration', 'broader TCR repertoire', 'enhanced systemic immune response', 'tumor antigen spreading'). Null if not discussed.</td>
                    </tr>
                    <tr>
                        <td><strong>tumor_microenvironment_changes</strong></td>
                        <td>str</td>
                        <td>Any reported changes in the tumor microenvironment with neoadjuvant treatment (e.g. 'increased PD-L1 expression', 'tertiary lymphoid structures', 'immune cell infiltration patterns'). Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>biomarkers_predictive</strong></td>
                        <td>str</td>
                        <td>Any biomarkers identified as predictive of response to neoadjuvant vs adjuvant therapy. Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>adverse_events</strong></td>
                        <td>str</td>
                        <td>Safety profile and adverse events, particularly comparing neoadjuvant-adjuvant vs adjuvant-only if available (e.g. 'Grade 3-4 AEs: 30% neoadjuvant vs 25% adjuvant'). Null if not reported.</td>
                    </tr>
                    <tr>
                        <td><strong>comparative_advantage</strong></td>
                        <td>str</td>
                        <td>If the study directly compares neoadjuvant-adjuvant vs adjuvant-only, summarize the key advantages or disadvantages found for the neoadjuvant approach in a concise, information-dense way.</td>
                    </tr>
                    <tr>
                        <td><strong>hypothesized_mechanism</strong></td>
                        <td>str</td>
                        <td>Any hypotheses or proposed mechanisms by the authors for why neoadjuvant timing might improve outcomes (e.g. 'in situ vaccination effect', 'immune priming with intact tumor', 'prevention of surgery-induced immunosuppression'). Null if not discussed.</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>